Bioline Rx Gross Profit

Bioline Rx (BLRX) currently reports a gross profit of $4.9M as of June 2026. That compares with $14M in the prior-year period — down 65.7% year over year. That is below the Healthcare sector average of $65B. Use the charts on this page to explore Bioline Rx's gross profit history and peer comparisons.

Bioline Rx's gross profit decreased from $14M to $4.9M — a 65.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Bioline Rx's gross profit of $4.9M is lower than the Healthcare sector average of $65B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Bioline Rx reported $4.9M in gross profit as of June 2026. That compares with $14M in the prior-year period — down 65.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $4.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $65B. From there, open related valuation or income-statement pages for Bioline Rx, and consider following BLRX for alerts when major investors trade the stock.